Search

everythinglearnresearchcommunity

for

Search:↓

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.

Both scalp cooling and chemical cooling caps effectively prevent hair loss in breast cancer patients undergoing chemotherapy.

Chemotherapy for breast cancer often causes significant and lasting hair loss.

The document concludes that drug repurposing, which is reusing known medicines for new illnesses, can provide faster, cheaper treatment options for various serious diseases, including cancer, COVID-19, and rare diseases.

Sulforaphane from broccoli may help treat certain cancers, hormone issues, and hair loss.

Sodium pentaborate pentahydrate can increase hair growth and improve hair quality at certain doses.

Sheep wool follicles absorb different amino acids at various rates and locations, which could affect wool growth based on diet and genetics.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

PPX causes much less hair loss than traditional taxanes.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

The new nanoparticles could improve melanoma treatment by working better than current options.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Human hair-derived particles can effectively carry and release the cancer drug Paclitaxel in a pH-sensitive manner, potentially targeting cancer cells while sparing healthy ones.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Most patients experienced significant but reversible hair loss during treatment.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Scalp cooling therapy helped over 80% of women keep at least half their hair during chemotherapy.

The treatment was effective and tolerable for advanced gastric cancer.

Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.

Docetaxel is effective against various cancers but mainly causes neutropenia.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.